Christmas lunch; 2020 walks

The Christmas lunch will be on December 11 at the Coach & Horses, Clifton, on December 11. The menu with links to the organiser is available here (Christmas Menu 2019.pdf). The next BAWA members’ meeting will be on Monday January 13 2020. More later – directions here. And Chris Millett will lead next year’s walks: Spring one Friday April 3 Ashton Court, autumn one Friday October 2. Clapton in Gordano. More later.

Coffee mornings held at the Macmillan Centre, Southmead Hospital, on the first Thursday of each month (10am-12.30), to help new patients. A few more members are needed to help out. Please contact our chairman.

New hope for advanced cancer men

A new treatment is being tested that could extend the lives of men with advanced prostate cancer, by killing cancer in the prostate despite the disease having already spread. The nationwide Atlanta trial, at Imperial College London, is to recruit 918 men newly-diagnosed with advanced prostate cancer. Read more here.  And positive results have been reported from a clinical trial that tested the PARP-inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer who have alterations in certain DNA damage repair genes. Roughly 20-30% of these patients harbour these gene mutations in their tumours and thus may benefit from olaparib.

New tests on the cards

A simple new blood test has been found to efficiently and accurately detect aggressive prostate cancer, according to research by Queen Mary University of London. In combination with the PSA test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment. The results need to be validated in other independent research centres before the new test is available privately or on the NHS, which could take 3-5 more years (Oct ’19). See more here. And UK researchers have developed a urine test to diagnose aggressive prostate cancer and predict whether patients will need treatment up to five years earlier than standard clinical methods (Jun ’19). See more here

Tracking down tumours

A radical ‘seek and destroy’ treatment could extend the lives of thousands of men with advanced prostate cancer. The approach is described by experts as ‘game changing’ (Jun ’19). See more at

MRI scans to replace PSA?

Hundreds of UK men are trying out a non-invasive MRI scan for prostate cancer to see if it should eventually be offered routinely on the NHS. The scan takes images to check for any abnormal growths. It will take a few years to know if MRI will be better than PSA tests and biopsies at spotting cancers (Jun ’19). Prostate Cancer UK said the news made headlines but journalists “can be overly enthusiastic about new research” and put the record straight here:

A first for advanced patients

GenesisCare announced that the first UK patients have been treated with Theranostics personalised treatment for advanced prostate cancer outside a clinical trial. This is the first time this treatment has been clinically available in the UK, bringing new hope for patients with late stage prostate cancer (Jun ’19). More info here. And videos of patients who are have had the PSMA therapy and want to share their experience are available here. And there are individual patients’ experiences here
and here

Drugs to attack resistant cancer

The world’s first drugs designed to stop cancer cells becoming resistant to treatment could be available within the next decade, scientists have said. A ÂŁ75m investment to develop the drugs has been announced by the Institute of Cancer Research (May ’19). See more here

Help with treatment – but beware

AN NHS tool is now available – intended for men with non-metastatic prostate cancer who are deciding between conservative and radical management regimes. It is intended only for men with non-metastatic prostate cancer who are deciding between conservative and radical management regimes. It’s recommend that patients use this tool in consultation with their doctor (Apr ’19). See here. You may have read about this tool in newspapers, but not all the news was 100% accurate – check this NHS Behind The Headlines Page for the facts.. And four new technologies that will tame the immune system are getting us closer to a future where cancer becomes curable. See more here

Cancer survival rates published

Public Health England has published a statistical bulletin on survival rates (1-year and 5-year) for many types of cancer based on more recent data than previously available. If PCa is diagnosed at stages 1, 2 or 3, the 1-year survival rate is as good as for everyone else and the 5-year rate is the same for stages 1 and 2 (>96% for stage 3). Hence the importance of early diagnosis. A summary of the stats is to be found here with a link to the full report

A Bristol first – and sparing nerves

A Bristol man is the first NHS patient to have a device implanted which can reduce the side effects of radiotherapy by 70%. Alan Clarke first had radiotherapy in 2011 but the cancer returned. He was selected to be first to receive the spacer because he was considered to be more at risk of suffering side effects from a second course of radiotherapy (see more here). And a trial to spare the nerves around the prostate during surgery is being held at Southmead Hospital. if successful, it will reduce the risk of erectile disfunction and will be available throughout England. The trial featured on BBC Points West on January 23 ’19.

New guidance on active surveillance

New best-practice guidelines for doctors offering active surveillance have been published, as NICE recognise the procedure as being on a par with surgery and radiotherapy for men with low-risk localised prostate cancer (May ’19). More here. And Prostate Cancer UK run a monthly group chat from men on active surveillance who want to share experiences and ask questions about the treatment. The group chat is on the second Tuesday of the month (7-8pm). Join the chat here. More news on the Newsletter page.